Skip to main content
Top
Published in: Lung 4/2015

01-08-2015

Prognosis and Predictors of Rebleeding After Bronchial Artery Embolization in Patients with Active or Inactive Pulmonary Tuberculosis

Authors: Seo Woo Kim, Seok Jeong Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang, Sung Shine Shim, Yookyung Kim

Published in: Lung | Issue 4/2015

Login to get access

Abstract

Introduction

The aim of this study was to characterize the prognosis and identify factors that contribute to rebleeding after bronchial artery embolization (BAE) in patients with active or inactive pulmonary tuberculosis (PTB).

Methods

Following a retrospective review, 190 patients had hemoptysis requiring BAE due to PTB in one hospital between 2006 and 2013.

Results

The median age at the time of diagnosis of PTB was 37 years and 54 years at the time of first episode of hemoptysis. Among 47 patients (24.7 %) who experienced rebleeding after BAE during the median follow-up period of 13.9 months [interquartile range (IQR) 2.3–36.0 months], bleeding recurred in 12 patients (6.3 %) within 1 month and in 15 patients (7.9 %) after 1 year. The median non-recurrence time was 8.6 months (IQR 1.2–27.6 months). Independent predictors of rebleeding after BAE were tuberculous-destroyed lung [hazard ratio (HR) 3.0; 95 % confidence interval (CI) 1.5–6.2; p = 0.003], the use of anticoagulant agents and/or antiplatelet agents (HR 2.6; 95 % CI 1.1–5.8; p = 0.022), underlying chronic liver disease (HR 2.7; 95 % CI 1.1–4–6.9; p = 0.033), elevated pre-BAE C-reactive protein (CRP) (mg/dL) (HR 2.4; 95 % CI 1.0–5.5; p = 0.048), and the existence of fungal ball (HR 2.1; 95 % CI 1.0–4.3; p = 0.050).

Conclusions

The risk of rebleeding after BAE in active or inactive PTB was high, particularly in patients with tuberculous-destroyed lung, chronic liver disease, the use of anticoagulant agents and/or antiplatelet agents, elevated pre-BAE CRP, and the existence of fungal ball.
Literature
1.
go back to reference Shin BS, Jeon GS, Lee SA et al (2011) Bronchial artery embolisation for the management of haemoptysis in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 15:1093–1098PubMedCrossRef Shin BS, Jeon GS, Lee SA et al (2011) Bronchial artery embolisation for the management of haemoptysis in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 15:1093–1098PubMedCrossRef
2.
go back to reference Sopko DR, Smith TP (2011) Bronchial artery embolization for hemoptysis. Semin Interv Radiol 28:48–62CrossRef Sopko DR, Smith TP (2011) Bronchial artery embolization for hemoptysis. Semin Interv Radiol 28:48–62CrossRef
3.
go back to reference Yoo DH, Yoon CJ, Kang SG et al (2011) Bronchial and nonbronchial systemic artery embolization in patients with major hemoptysis: safety and efficacy of N-butyl cyanoacrylate. Am J Roentgenol 196:W199–204CrossRef Yoo DH, Yoon CJ, Kang SG et al (2011) Bronchial and nonbronchial systemic artery embolization in patients with major hemoptysis: safety and efficacy of N-butyl cyanoacrylate. Am J Roentgenol 196:W199–204CrossRef
4.
go back to reference Lee JH, Kwon SY, Yoon HI et al (2007) Haemoptysis due to chronic tuberculosis vs. bronchiectasis: comparison of long-term outcome of arterial embolisation. Int J Tuberc Lung Dis 11:781–787PubMed Lee JH, Kwon SY, Yoon HI et al (2007) Haemoptysis due to chronic tuberculosis vs. bronchiectasis: comparison of long-term outcome of arterial embolisation. Int J Tuberc Lung Dis 11:781–787PubMed
5.
go back to reference Kim YG, Yoon HK, Ko GY et al (2006) Long-term effect of bronchial artery embolization in Korean patients with haemoptysis. Respirology 11:776–781PubMedCrossRef Kim YG, Yoon HK, Ko GY et al (2006) Long-term effect of bronchial artery embolization in Korean patients with haemoptysis. Respirology 11:776–781PubMedCrossRef
6.
go back to reference Hwang HG, Lee HS, Choi JS et al (2013) Risk factors influencing rebleeding after bronchial artery embolization on the management of hemoptysis associated with pulmonary tuberculosis. Tuberc Respir Dis (Seoul) 74:111–119CrossRef Hwang HG, Lee HS, Choi JS et al (2013) Risk factors influencing rebleeding after bronchial artery embolization on the management of hemoptysis associated with pulmonary tuberculosis. Tuberc Respir Dis (Seoul) 74:111–119CrossRef
7.
go back to reference Chun JY, Belli AM (2010) Immediate and long-term outcomes of bronchial and non-bronchial systemic artery embolisation for the management of haemoptysis. Eur Radiol 20:558–565PubMedCrossRef Chun JY, Belli AM (2010) Immediate and long-term outcomes of bronchial and non-bronchial systemic artery embolisation for the management of haemoptysis. Eur Radiol 20:558–565PubMedCrossRef
8.
go back to reference Chan VL, So LK, Lam JY et al (2009) Major haemoptysis in Hong Kong: aetiologies, angiographic findings and outcomes of bronchial artery embolisation. Int J Tuberc Lung Dis 13:1167–1173PubMed Chan VL, So LK, Lam JY et al (2009) Major haemoptysis in Hong Kong: aetiologies, angiographic findings and outcomes of bronchial artery embolisation. Int J Tuberc Lung Dis 13:1167–1173PubMed
9.
go back to reference Mossi F, Maroldi R, Battaglia G et al (2003) Indicators predictive of success of embolisation: analysis of 88 patients with haemoptysis. Radiol Med 105:48–55PubMed Mossi F, Maroldi R, Battaglia G et al (2003) Indicators predictive of success of embolisation: analysis of 88 patients with haemoptysis. Radiol Med 105:48–55PubMed
10.
go back to reference Yu-Tang Goh P, Lin M, Teo N et al (2002) Embolization for hemoptysis: a six-year review. Cardiovasc Interv Radiol 25:17–25CrossRef Yu-Tang Goh P, Lin M, Teo N et al (2002) Embolization for hemoptysis: a six-year review. Cardiovasc Interv Radiol 25:17–25CrossRef
11.
go back to reference Osaki S, Nakanishi Y, Wataya H et al (2000) Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 67:412–416PubMedCrossRef Osaki S, Nakanishi Y, Wataya H et al (2000) Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 67:412–416PubMedCrossRef
13.
go back to reference Im JG, Itoh H, Shim YS et al (1993) Pulmonary tuberculosis: CT findings–early active disease and sequential change with antituberculous therapy. Radiology 186:653–660PubMedCrossRef Im JG, Itoh H, Shim YS et al (1993) Pulmonary tuberculosis: CT findings–early active disease and sequential change with antituberculous therapy. Radiology 186:653–660PubMedCrossRef
15.
go back to reference Bobrowitz ID, Rodescu D, Marcus H, Abeles H (1974) The destroyed tuberculous lung. Scand J Respir Dis 55:82–88PubMed Bobrowitz ID, Rodescu D, Marcus H, Abeles H (1974) The destroyed tuberculous lung. Scand J Respir Dis 55:82–88PubMed
16.
go back to reference Ryu YJ, Lee JH, Chun EM et al (2011) Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis 15:246–250PubMed Ryu YJ, Lee JH, Chun EM et al (2011) Clinical outcomes and prognostic factors in patients with tuberculous destroyed lung. Int J Tuberc Lung Dis 15:246–250PubMed
17.
go back to reference Cremaschi P, Nascimbene C, Vitulo P et al (1993) Therapeutic embolization of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis. Angiology 144:295–299CrossRef Cremaschi P, Nascimbene C, Vitulo P et al (1993) Therapeutic embolization of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis. Angiology 144:295–299CrossRef
18.
go back to reference Stoll JF, Bettmann MA (1998) Bronchial artery embolization to control hemoptysis: a review. Cardiovasc Interv Radiol 11:263–269CrossRef Stoll JF, Bettmann MA (1998) Bronchial artery embolization to control hemoptysis: a review. Cardiovasc Interv Radiol 11:263–269CrossRef
20.
go back to reference Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428PubMedCrossRef Palareti G, Leali N, Coccheri S et al (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428PubMedCrossRef
21.
go back to reference Serebruany VL, Malinin AI, Eisert RM et al (2004) Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 75:40–47PubMedCrossRef Serebruany VL, Malinin AI, Eisert RM et al (2004) Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 75:40–47PubMedCrossRef
22.
go back to reference Caldwell SH, Hoffman M, Lisman T et al (2006) Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 44:1039–1046PubMedCrossRef Caldwell SH, Hoffman M, Lisman T et al (2006) Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 44:1039–1046PubMedCrossRef
23.
go back to reference Lagrand WK, Visser CA, Hermens WT et al (1999) C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100:96–102PubMedCrossRef Lagrand WK, Visser CA, Hermens WT et al (1999) C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100:96–102PubMedCrossRef
24.
go back to reference Erlinger TP, Platz EA, Rifai N et al (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585–590PubMedCrossRef Erlinger TP, Platz EA, Rifai N et al (2004) C-reactive protein and the risk of incident colorectal cancer. JAMA 291:585–590PubMedCrossRef
25.
go back to reference Liu S, Ren J, Xia Q et al (2013) Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn’s disease from intestinal lymphoma, intestinal tuberculosis and Behcet’s syndrome. Am J Med Sci 346:467–472PubMedCrossRef Liu S, Ren J, Xia Q et al (2013) Preliminary case-control study to evaluate diagnostic values of C-reactive protein and erythrocyte sedimentation rate in differentiating active Crohn’s disease from intestinal lymphoma, intestinal tuberculosis and Behcet’s syndrome. Am J Med Sci 346:467–472PubMedCrossRef
26.
go back to reference Pepys MB, Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141–212PubMedCrossRef Pepys MB, Baltz ML (1983) Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 34:141–212PubMedCrossRef
Metadata
Title
Prognosis and Predictors of Rebleeding After Bronchial Artery Embolization in Patients with Active or Inactive Pulmonary Tuberculosis
Authors
Seo Woo Kim
Seok Jeong Lee
Yon Ju Ryu
Jin Hwa Lee
Jung Hyun Chang
Sung Shine Shim
Yookyung Kim
Publication date
01-08-2015
Publisher
Springer US
Published in
Lung / Issue 4/2015
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-015-9728-4

Other articles of this Issue 4/2015

Lung 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine